anticoagulant

systematic review meta-analysis network meta-analysis

Select acute coronary syndromeacute myocardial infarctioncardiovascular preventioncoronary artery diseaseheart failurepercutaneous coronary interventionperipheral vascular diseasespost myocardial infarctionpost strokethrombosis prevention ACS (excluding AMI)All ACS (including AMI)All type of patientuncoded clinical condition ***orthopedic surgeryprimary preventionsecondary prevention       ADOanticoagulantantivitamins Kdirect factor Xa inhibitorsdirect oral anticoagulantdirect thrombin inhibitorLow Molecular Weight HeparinNOACoral anticoagulantoral direct thrombin inhibitororal factor Xa inhibitorVKAVKA + antiplatelet wafarinacenocoumarolapixabanbivalirudincoumadindabigatrandalteparindicoumaroledoxabanenoxaparinfondaparinuxotamixabanphenindionereviparinrivaroxabanwarfarinximelagatran vs heparinvs heparin + anti Gp2b3avs placebo and controlvs placebo or controlvs placebo or no treatmentvs antiplatelet drugsvs Danaparoidvs Dextranvs intermittent pneumatic compressionvs Low molecular weight heparinvs UFHvs unfractionated heparin      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Major bleeding (100)All cause death (84)myocardial infarction (fatal and non fatal) (47)Deep vein thrombosis (46)ischemic stroke (33)total VTE and all-cause mortality (32)Minor bleeding (31)proximal DVT (31)Coronary event (29)major VTE (fatal and non fatal DVT,PE) (27)intracranial hemorrhage (26)major or clinically relevant non-major bleeding (25)distal DVT (25)all cause death, non-fatal MI, thrombo-embolic stroke (23)non-fatal pulmonary embolism (20)Symptomatic deep-vein thrombosis (17)Revascularization (16)asymptomatic DVT (15)Extracranial hemorrhage (14)Symptomatic venous thromboembolism (DVT, PE) (14)cardiovascular events (10)stroke (fatal and non fatal) (10)Cardiovascular death (9)MACE (9)Bleeding (9)Coronary death (8)all cause death, MI, thrombo-embolic stroke (6)Fatal stroke (6)any bleedings (5)Unplanned revascularisation for ischaemia (5)Non fatal MI (4)Haemmorhagic stroke (4)cardiac event (fatal and non fatal ) (3)Fatal bleeding (3)death, MI, unplanned revascularization (3)stent thrombosis (2)major or minor bleeding (2)Amputation (2)exacerbation of heart failure (2)net benefit (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Major bleeding	All cause death
acute coronary syndrome
apixaban
APPRAISE-1 (10mg od), 2009      NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE-1 (2.5 mg bid), 2009      NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE 2, 2011      NCT	apixaban	placebo			Low risk of bias	negative
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002	coumadin	control (on top of aspirin)				suggesting
ASPECT-2 (coumadin vs aspirin), 2002	coumadin	aspirin				suggesting
dabigatran
REDEEM, 2009    NCT	dabigatran	placebo			Low risk of bias	negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCT	otamixaban	unfractionated heparin			Low risk of bias	suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCT	rivaroxaban 2.5mg	placebo			Low risk of bias	suggesting
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCT	rivaroxaban 2.5mg	placebo			Low risk of bias	negative
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCT	rivaroxaban 5mg	placebo				suggesting
ATLAS ACS-TIMI 46 (5mg), 2009      NCT	rivaroxaban 5mg	placebo			Low risk of bias	negative
warfarin
ATACS (pilot study) (warfarin vs control), 1990	warfarin	control (on top of aspirin)				negative
ATACS, 1994	warfarin	control (on top of aspirin)				negative
CARS, 1997	warfarin	control (on top of aspirin)				negative
OASIS Pilot (phase 1), 1998	warfarin	control (on top of aspirin)				negative
OASIS Pilot (phase 2), 1998	warfarin	control (on top of aspirin)				negative
OASIS-2 Warfarin Substudy, 2001	warfarin	control (on top of aspirin)				negative
APRICOT-2, 2002	warfarin	control (on top of aspirin)				negative
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
WARIS, 2002	warfarin	control (on top of aspirin)				suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)				negative
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	negative
Huyhn, 2001	warfarin	placebo (on top of aspirin)			Low risk of bias	negative
ATACS (pilot study) warfarin vs aspirin, 1990	warfarin	aspirin				negative
ximelagatran
ESTEEM, 2003	ximelagatran	placebo			Exploratory	-
acute myocardial infarction
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)				negative
ASPECT, 1994	coumadin	placebo			Low risk of bias	suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin				suggesting
warfarin
APRICOT-2, 2002	warfarin	control (on top of aspirin)				suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
WARIS, 1999	warfarin	control (on top of aspirin)			Low risk of bias	-
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Risk of bias	suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)				suggesting
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	suggesting
WARIS II (warfarin alone), 2002	warfarin	aspirin				suggesting
cardiovascular prevention
dicoumarol
Apenstrom and Korsan-Bengtsen, 1964	dicoumarol	no anticoagulant				-
rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCT	rivaroxaban	aspirin	secondary prevention			-
COMPASS (rivaroxaban + aspirin), 2017      NCT	rivaroxaban + aspirin	aspirin	secondary prevention		Low risk of bias	-
wafarin
WARIS, 1990	warfarin	placebo			Low risk of bias	-
warfarin
Thrombosis Prevention trial (Warfarin), 1998        NCT	warfarin	placebo	primary prevention		Low risk of bias	suggesting
Thrombosis Prevention trial (W plus A), 1998        NCT	warfarin + aspirin	placebo	primary prevention		Low risk of bias	suggesting
coronary artery disease
dicoumarol
Apenstrom and Korsan-Bengtsen, 1964	dicoumarol	no anticoagulant				-
wafarin
WARIS, 1990	warfarin	placebo			Low risk of bias	-
heart failure
rivaroxaban
COMMANDER HF, 2018      NCT	rivaroxaban	placebo				negative
warfarin
HELAS (warfarin vs placebo), 2006	warfarin	placebo			Low risk of bias	-
HELAS (warfarin vs aspirin), 2006	warfarin	aspirin			Low risk of bias	-
WATCH (warfarin vs aspirin), 2009      NCT	warfarin	aspirin				suggesting
percutaneous coronary intervention
bivalirudin
REPLACE-2, 2003	bivalirudin	heparin + GP2b3a inhibitors			Low risk of bias	-
HORIZONS-AMI (Stone), 2008        NCT	bivalirudin	heparin + GP2b3a inhibitors			Risk of bias	suggesting
ACUITY (Stone) (bivalirudin alone), 2006      NCT	bivalirudin	heparin + GP2b3a inhibitors			Risk of bias	-
Kleiman, 2002	bivalirudin + eptifibatide	heparin + GP2b3a inhibitors			Exploratory	-
ISAR-REACT 3, 2008    NCT	bivalirudin	UFH			Low risk of bias	-
REPLACE-1, 2004	bivalirudin	UFH			Exploratory	negative
BAT (Bittl), 1995	bivalirudin	UFH			Low risk of bias	suggesting
ARMYDA BIVALVE	bivalirudin	UFH				-
NAPLES (Tavano), 2009	bivalirudin	UFH plus tirofiban			Risk of bias	suggesting
dalteparin
Natarajan (without antiGp2b3a), 2003	dalteparin	UFH				-
Natarajan (+ antiGp2b3a), 2003	dalteparin	UFH + anti Gp2b3a				-
enoxaparin
STEEPLE, 2006      NCT	enoxaparin	UFH			Risk of bias	-
Rabah, 1999	enoxaparin	UFH			Exploratory	negative
CRUISE, 2003	enoxaparin	UFH			Exploratory	negative
Galeote, 2001	enoxaparin	UFH				negative
Dudek, 2000	enoxaparin	UFH				negative
Dudek b (enox alone), 2000	enoxaparin	UFH				-
Drozd, 2001	enoxaparin	UFH				negative
ATOLL, 2010	enoxaparin	UFH			Risk of bias	-
Dubek b (+abciximal), 2001	enoxaparin+abciximab	UFH				-
reviparin
REDUCE, 1996	reviparin	UFH			Low risk of bias	suggesting
peripheral vascular diseases
warfarin
Johnson, 2002	warfarin	contrôle				-
Sarac, 1998	warfarin	contrôle				-
post myocardial infarction
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)				negative
ASPECT, 1994	coumadin	placebo			Low risk of bias	suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin				suggesting
warfarin
APRICOT-2, 2002	warfarin	control (on top of aspirin)				suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
WARIS, 1999	warfarin	control (on top of aspirin)			Low risk of bias	-
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Risk of bias	suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)				suggesting
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	suggesting
WARIS II (warfarin alone), 2002	warfarin	aspirin				suggesting
post stroke
dicoumarol
Howard, 1963	dicoumarol	placebo				negative
Nat-Coop, 1962	dicoumarol	placebo				suggesting
phenindione
Enger, 1965	phenindione	placebo				negative
Thygesen, 1964	phenindione	placebo				negative
rivaroxaban
NAVIGATE ESUS, 2018      NCT	rivaroxaban	aspirin				-
warfarin
SWAT, 1998	warfarin	aspirin				negative
thrombosis prevention
acenocoumarol
Hamulyak, 1994	Acenocoumarol	Nadroparin				negative
Samama, 2001	Acenocoumarol	Reviparin				negative
van Geloven, 1977	Acenocoumarol	unfractionated heparin			Low risk of bias	-
apixaban  </